Rethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is redefining how we predict, diagnose, and develop treatments for neurodegenerative diseases.
This roundtable discussion brings together two leading experts in neurology as they explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. Tony Wyss-Coray, PhD (Stanford University School of Medicine) discusses how combining protein measurements in blood and cerebrospinal fluid with genetic data has revealed valuable insights into brain aging. Jacob Vogel, PhD (Lund University) presents discoveries from the Global Neurodegeneration Proteomics Consortium that reveal protein signatures that can predict dementia, identify multiple pathologies, and track changes in protein networks over time. The conversation is moderated by Steve Williams, MD, PhD, Chief Medical Officer at Standard BioTools.
In this webinar you’ll learn:
- How measuring more than 6,000 individual proteins in 1,956 participants offered insights to illuminate the mechanisms of weight management and metabolic health, providing a deeper understanding of how semaglutide may exert its effects
- Why incorporating proteomic data early in clinical trial design can optimize the discovery of novel biomarkers and inform targeted treatment strategies for obesity and related conditions
- How real-world proteomic profiles reveal potential benefits for disease-specific proteomic signatures
Tony Wyss-Coray, PhD
D.H. Chen Distinguished Professor of Neurology and Neurological Sciences & Director of the Phil and Penny Knight Initiative for Brain Resilience, Stanford University
Dr. Tony Wyss-Coray is the D.H. Chen Distinguished Professor of Neurology at Stanford and directs the Knight Initiative for Brain Resilience. His research focuses on brain aging, Alzheimer’s, and how blood factors influence brain function. His team showed that young blood can rejuvenate aging brains. He uses genetic, cell biology, and –omics tools in killifish, mice, and humans. Wyss-Coray has spoken at TED, the World Economic Forum, and more. He co-founded Alkahest and other biotech companies and has received major awards including the NIH Pioneer Award and recognition in Time’s “Health Care 50.”
Jacob Vogel, PhD
Assistant Professor / Associate Senior Lecturer, Lund University
Dr. Jacob Vogel is an Assistant Professor at Lund University specializing in neurodegenerative research. His lab uses large datasets, including neuroimaging and multi-omics, to model disease progression in Alzheimer’s and Parkinson’s. He is known for identifying Alzheimer’s subtypes and his expertise in tau imaging. Committed to open science, he collaborates with research networks like the Swedish BioFINDER study. His work aims to develop biological models to inform diagnostics and clinical applications.
Rethinking Neurodegeneration Through Blood-Based Biomarkers
A presentation by Tony Wyss-Coray, PhD and Jacob Vogel, PhD
More webinars
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.